Radiation-Immuno combo targets tough liver cancer clot

NCT ID NCT06823375

Recruiting now Disease control Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether adding precise, high-dose radiation (SBRT) to standard immunotherapy drugs (atezolizumab plus bevacizumab) can help people with advanced liver cancer that has spread into the main portal vein. About 40 participants will receive the combination. The goal is to see if this approach improves survival and tumor control for this hard-to-treat group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Atezolizumab plus bevacizumab (immunotherapy drugs) and stereotactic body radiotherapy (precise high-dose radiation)
What this could lead to: If successful, this combination could improve survival and tumor control for people with advanced liver cancer and major portal vein tumor thrombosis, a group with very poor prognosis.
What could go wrong: This is a small, early-phase trial (40 participants) without a control group, so results may not be definitive. The added radiation could increase side effects, and the benefit over standard treatment is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC

Contacts and locations

Locations

Department of Clinical Oncology, Prince of Wales Hospital
RECRUITING

Hong Kong, Hong Kong
Department of Clinical Oncology, Tuen Mun Hospital
RECRUITING

Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.